Email from Brean Analyst covering Pernix

Quote

Wall Street Grinder

Guest
The below email was received this morning from Difei Yang from Brean Capital (Analyst covering Pernix stock). I post here as I also believe his response will be of interest to sales reps (as well as investors).



From: Jonathan Aschoff
Sent: Monday, July 11, 2016 7:32 AM
To: Difei Yang
Subject: FW: Question

Hi, Steven,


I do not believe a buy-out is on the horizon- more likely to be a 2017 event. People are scared of the spec pharma right now. PTX needs to lift the debt overhang to get its reasonable valuation back.


Hope this helps,


Difei Yang

Equity Research _______________________ Brean Capital, LLC 1345 Avenue of the Americas - 29th Floor
New York, NY 10105-0007
Tel: (212) 702-6652 | Fax: 212-702-6649
Mobile: (973) 985-4796
 






Below is a follow up email from Mr. Yang (I do ask that others do not bombard him with any emails of calls as he was nice enough to honestly answer my questions). I like to keep this relationship so that I can ask him any future questions sales reps or investors may have. If he gets multiple emails on pernix, it probably will stop returning emails/calls... Thank you



Hi, Steve,


Wall street probably does not care much about the Q2 rev as long as it does not dip too much below consensus number.



Knowing Sanjay Patel, the cfo of the company. I do not expect he will replace the current debt with toxic financing. I do not believe they need the toxic financing either to meet the Feb/2016 obligation. They could have upsides from the GSK settlement. I think they also have additional room on SG&A side.


Difei Yang Managing Director & Senior Analyst
Equity Research _______________________ Brean Capital, LLC 1345 Avenue of the Americas - 29th Floor
New York, NY 10105-0007
 






Wall Street Grinder said:
Below is a follow up email from Mr. Yang (I do ask that others do not bombard him with any emails of calls as he was nice enough to honestly answer my questions). I like to keep this relationship so that I can ask him any future questions sales reps or investors may have. If he gets multiple emails on pernix, it probably will stop returning emails/calls... Thank you



Hi, Steve,


Wall street probably does not care much about the Q2 rev as long as it does not dip too much below consensus number.



Knowing Sanjay Patel, the cfo of the company. I do not expect he will replace the current debt with toxic financing. I do not believe they need the toxic financing either to meet the Feb/2016 obligation. They could have upsides from the GSK settlement. I think they also have additional room on SG&A side.


Difei Yang Managing Director & Senior Analyst
Equity Research _______________________ Brean Capital, LLC 1345 Avenue of the Americas - 29th Floor
New York, NY 10105-0007
Click to expand...

Thanks for sharing Steve. I honestly can't believe that you just posted all of this guys contact information to a public forum.
 






Mr Yang has published analysts reports on the financial news media wires - so his contact information is public. He is not an insider, but an analyst for Brean Capital, LLC that is following Pernix. However, you are correct, I should NOT have published his telephone number as I hate for him to get bombarded with calls or even emails from ST folks.

The WS Grinder
 


















Just a little research will review the truth and lies. Maybe WS made a mistake or maybe not. Like most rumors on this board is a lie and once in a while there is some truth.

The Dr. has been wrong on many occasion regarding Pernix.
 






The WS Grinder does not lie. Seriously , how am I suppose to know by an email that he is a she. Geez, we have a hard time now in in person determining gender. Believe what you want, those emails I recvd back from HER have both positive and negative news.

The WS Grinder
 






It is good for employees that a buy out will not take place until 2017 (bad for investors) for the reasons that analyst stated. But good news for both employees and investors that no toxic financing on the large debt will take place in the near term. So the success or failure of Pernix from both an employee and investor standpoint now depends on management and the sales rep who still have jobs turning the company around financially.
 






Wall Street Grinder said:
The below email was received this morning from Difei Yang from Brean Capital (Analyst covering Pernix stock). I post here as I also believe his response will be of interest to sales reps (as well as investors).



From: Jonathan Aschoff
Sent: Monday, July 11, 2016 7:32 AM
To: Difei Yang
Subject: FW: Question

Hi, Steven,


I do not believe a buy-out is on the horizon- more likely to be a 2017 event. People are scared of the spec pharma right now. PTX needs to lift the debt overhang to get its reasonable valuation back.


Hope this helps,


Difei Yang

Equity Research _______________________ Brean Capital, LLC 1345 Avenue of the Americas - 29th Floor
New York, NY 10105-0007
Tel: (212) 702-6652 | Fax: 212-702-6649
Mobile: (973) 985-4796
Click to expand...
 












Jonathan works with Ms Yang. The original email sent to Brean Capital was to Jonathan. Ms Yang was the person at Brean Capital that responded.
If you do not believe, just go to Brean Capital Web site and see who Jonathan is. He works with Ms Yang as a Biotech research analyst.

The WS Grinder
 












Top Bottom
Back
Quote